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1. Introduction
The application of the prototype antibiotics penicillin and streptomycin to bacterial infection
in the 1940’s marked a historic milestone in medicine and heralded a new era of antimicrobial
therapy as the modern standard for infectious disease management. Yet, even in those early
days of discovery, scientist Joseph Bigger noted an unexplained phenomenon. Although
penicillin treatment of Staphylococcus aureus infection killed the great majority of the bacterial
population, a small subset of cells (~1 in 105) continued to persist and remained recalcitrant to
antibiotic-mediated killing.[1] When re-grown in the absence of antibiotic, the bacterial
community once again became sensitive to antibiotic-mediated killing and resembled the
original culture (~1 in 105 persisters), providing conclusive proof that these organisms were
not drug-resistant strains that had evolved via genetic mutations (in which case all bacteria in
the final population would be drug-resistant). (Fig. 1) Instead, persister cells are phenotypic
variants that are genetically identical to the susceptible bacterial population, but have modified
their physiology to survive environmental stress. These bacteria exhibit antibiotic tolerance
that is non-heritable and reversible upon removal of the antibiotic, a completely different
phenomenon than the more well-studied antibiotic resistance mechanisms mediated by
genetic mutation. Persistence is akin to a community “insurance policy” in which surviving
persister cells hedge against unlikely but catastrophic events, while still maintaining near
optimal growth at the population level.[2, 3]
In this review, we will discuss the known molecular mechanisms that underlie bacterial
persistence, the impact of persistence on infectious disease, and the different strategies that
are being developed to target persisters in disease. The human toll of pathogen infection has
been compounded by the rampant use of antibiotics in the last half-century, leading to the
rapid evolution of drug-resistant strains to practically every approved antibiotic. There is a
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
great public health need to identify novel strategies for development of therapeutics to treat
pathogen infection. Development of novel therapies that either kill persisters directly or
stimulate their reversion to logarithmic growth may effectively reduce disease relapse and
shorten the treatment period.[4] It may be the case that a combination therapy comprised of
conventional antibiotics that kill replicating pathogens and new drugs that target the meta‐
bolically-inactive persisters can also reduce the rate of emergence of antibiotic resistance.
2. Impact of bacterial persistence on infectious disease
Without question, bacterial persistence greatly contributes to the burden of infectious disease,
where persisters survive antibiotic treatment to re-infect patients in a frustrating cycle of
chronic infection. Many antibiotics have been shown to be only active against dividing bacteria.
[5] Persisters are thought to be dormant cells that greatly slow down essential cellular functions
that antibiotics generally target, including trancription, translation, cell wall synthesis, and
DNA replication. Persisters are found at relatively higher levels in stationary phase compared
to logarithmic cultures, consistent with a dormant state. The persistence state has been found
in many different bacterial species, including E. coli, Mycobacterium tuberculosis, and Pseudo‐
monas aeruginosa, underscoring the evolution of persistence as a survival strategy in different
stressful environments.[6]
There is also increasing evidence that persisters mediate drug tolerance in biofilm formation
associated with chronic diseases, including endocarditis, gingivitis, and osteomyelitis.[7]
Biofilms form a protective environment for persisters, shielding them from the host immune
system.[8] (Fig. 2) Biofilms can form readily on in-dwelling devices, such as catheters and
prostheses, or on physiological surfaces, such as P. aeruginosa infection of the lung in cystic
fibrosis patients. The dormancy of persisters and the different pathways that lead to their
formation contribute to the unique challenge in treatment of chronic infections, especially in
immunocompromised patients where biofilms can form deep in the soft tissues. In addition,
the presence of different subpopulations of persistent pathogens with varying antiobiotic
susceptibilities further complicates treatment with optimizing drug efficiencies.
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Figure 1. Bacterial persisters are recalcitrant to antiiotic killing. After removal of antibiotic, bacterial community ex‐
pands to contain both wild-type and persister sub-groups, indicating that the persisters are phenotypic variants in‐
stead of containing genetic mutations.
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Figure 2. Biofilm formation with persisters. Biofilms can contain both wild-type replicating and persister cells. Addi‐
tion of antibiotics and host immunity can kill both wild-type and persister cells in the biofilm and extracellular milieu.
The biofilm matrix can protect persisters from killing and can lead to re-population of pathogen in the biofilm after
antibiotics are removed.
3. Molecular mechanisms of bacterial persistence
Despite observance of the persister phenotype since the 1940’s, the genetic regulatory path‐
ways that switch bacteria into the persister phenotype remain poorly understood. Further
research on bacterial persistence rapidly declined with the availability of potent antibiotics.
Furthermore, there were technical difficulties in obtaining sufficient numbers of persister cells
for analysis and a lack of sophisticated and sensitive methods to study rare biological events
at single cell resolution. With the recent emergence of antibiotic-resistant bacterial strains,
interest in the mechanisms of bacterial persistence has slowly resurged, amid rapid advances
in microfluidics and advanced imaging that can be applied to single cell analysis. [9, 10] A list
of genes and pathways linked to persistence is listed in Table 1.
In the 1980’s, a genetic screen was performed to select for E. coli mutants that exhibited
increased persistence in response to ampicillin exposure.[11] hipA (high persistence) was the
first gene identified that modulated the frequency of persister formation, with the gain-of-
function allele hipA7 inducing ~1% persisters in culture, an ~1000 fold increase in persisters
compared to a wild-type strain. HipA is a component of a toxin-antitoxin (TA) module that
plays a role in inhibition of protein and nucleic acid synthesis in response to stress. HipA
functions as a kinase that phosphorylates the essential translation factor Elongation Factor Tu
(EF-Tu) to inhibit translation.[12]
The increased level of persister cells has led to the use of hipA mutants in multiple studies on
bacterial persistence, including integration of microfluidics and single cell microscopy[13] and
microarray analysis.[14] These types of studies can enable quantitative analysis of single cell
behavior and gene expression dynamics to measure cell-to-cell heterogeneity in a clonal cell
population. For example, growth patterns of fluorescently-labeled E. coli hipA mutants in the
channels of a microfluidic device suggested that slow-growing persister cells were already
present in the bacterial culture prior to antibiotic exposure, suggesting that the persistent state
may partially stem from stochastic mechanisms.[13] This study led to the identification of two
different persister types. Type I persisters are non-growing cells that enter at stationary phase,
a dormant state that protects them from the lethal action of several antibiotics known to affect
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mainly actively growing cells. Type II persisters do not require a starvation signal to enter the
persister state and are continuously generated during exponential growth in a fashion that
seems to depend on the population size. Although Type I and II persisters exist in wild-type
populations of E. coli, their differentiation has only been achieved using time lapse single cell
microscopy. Bacterial cells were also shown to still express proteins for a short period of time
prior to entering into full dormancy, indicating a gradual downregulation of essential cellular
processes during switching to the persistence state.[15]
While HipA contributes to persistence in E. coli, the absence or poor conservation of hipA in
other bacteria that have exhibited persistence suggested the existence of other persistence
mechanisms. Several other genetic screens have led to identification of additional metabolic
genes that function in cell dormancy, including GlpD[16], an enzyme that functions in
glycerol-3-phosphate metabolism, PhoU[17], a negative regulator that inhibits energy metab‐
olism and nutrient transport, the global regulators DksA and DnaKJ[18], and the HipA-like
toxin proteins RelE and MazF.[19 - 21] Transient ectopic overexpression of chaperone DnaJ
and PmrC were also shown to increase the number of persisters by up to 1000-fold.[19]
There is also increasing evidence that bacterial communication via chemical signaling may
play a role in establishing persistence. Recently, indole signaling has been implicated in
triggering persistence, leading to enhancement of persister formation in E. coli by ~10-fold in
response to multiple antibiotics.[22] This indole signaling is dependent on activation of the
OxyR and phage-shock pathways and enables the bacterial community to alter its frequency
of persistence as a survival mechanism. Another mediator of bacterial cell-cell communica‐
tions, the quorum-sensing peptide CSP pheromone was also implicated in the formation of
stress-induced multidrug-tolerant persisters in the oral pathogen Streptococcus mutans, the
leading etiological agent of dental biofilm.[23] In addition, gaseous ammonia released by
stationary phase bacterial cultures was found to modify the antibiotic resistance spectrum of
bacterial neighbors.[24] Ammonia release increases the level of intracellular polyamines,
which modulates membrane permeability to different antibiotics.
These results suggest that persisters may form through independent parallel mechanisms and
do not follow a single linear regulatory pathway. The underlying commonality is that each of
these mechanisms leads to a small subset of quiescent or slowly-dividing cells within an
otherwise rapidly dividing population. The fact that the great majority of candidate persister
genes have been identified in E. coli leaves open the question of whether persistence mecha‐
nisms are universal or species-specific. For example, P. aeruginosa infection in cystic fibrosis
patients is thought to be exacerbated by persister cells in biofilm formation and subsequent
recalcitrance to antibiotic treatment.[25] However, the majority the E. coli persister gene
candidates do not have confirmed homologs in P. aeruginosa. An independent screen of a
transposon insertion library from P. aeruginosa identified a separate list of genes, including a
putative DNA helicase and type IV pilus response regulator, as putative persister genes.[26]
Another study developed computational algorithms based on systems biology data such as
transcriptomics profiles and functional interactions networks to predict novel M. tuberculosis
genes required for long-term persistence in mouse lungs.[27] In this study, 18 novel genes were
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experimentally validated to play a role in persistence. To date, clear understanding of the
molecular mechanisms that regulate persister formation has yet to emerge.
Table 1. Selected molecular pathways that lead to bacterial persistence
4. Toxin/Anti-toxin (TA) modules
One common gene family that has been linked to bacterial persistence is the TA loci, which
function in adaptation to rapidly changing environmental conditions in many bacteria and
Archaea.[28] TA modules are present in the genome of diverse bacteria, with more than 50
modules in Mycobacterium tuberculosis, a pathogen that enters dormancy as part of its disease
lifecycle. Type II TA modules typically encode for a pair of co-transcribed stress-inducible
proteins, a stable toxin that inhibits cell growth, and a more labile anti-toxin that regulates the
activity of its cognate toxin. (Fig. 3) The toxin and anti-toxin form a tight complex and repress
their own expression. Depletion of the anti-toxin leads to release of its cognate toxin, which
interferes with an essential cellular target, such as mRNA, DNA gyrase, or DNA helicase, to
induce cell cycle arrest or inhibit metabolic functions. There are three types of antitoxins: type
I TA antitoxins encode small antisense RNAs that repress toxin gene translation, type II loci
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encode protein antitoxins, and type III loci express small RNA antitoxins.[29 - 31] It should be
noted that the term ‘toxin’ can be considered a misnomer, since the toxin genes do not kill the
bacteria, but rather repress cell growth.
Since the initial mapping of the hipA toxin to a TA locus, several other studies have linked TA
function to bacterial persistence. E. coli becomes dormant if toxin levels exceed a specific
threshold, with the amount determining the length of time bacteria remains in dormancy.[32]
Persister cells increased their TA expression levels, and deletion of ten TA loci that encoded
for mRNA endonucleases in E. coli led to a marked reduction in frequency of persister
formation.[33] Furthermore, overexpression of the toxin can induce a persistence state from
which cells can be resuscitated by expression of anti-toxin gene transcription.[34] This evidence
supports a model in which TA loci play a key role in switching on the persistence state in
response to environmental stressors.
Other TA loci, in addition to hipA/B, have been implicated in mediating persistence. For
example, the toxin RelA has been shown to be required for the long-term survival and
persistence of M. tuberculosis in mice.[35] Interestingly, RelA encodes for (p)ppGpp synthetase,
which functions in the synthesis of (p)ppGpp, or guanosine tetra-and pentaphosphate, a
signaling molecule that has been shown to be indicative of the persistent state.[36] (p)ppGpp
is a central mediator of the stringent response, which modulates cell expression to survive
stress and nutrient limitations.[37] Persisters exhibit relatively higher levels of (p)ppGpp,
which is consistent with the slowed growth rate and metabolically inactive state in persisters.
Damage of DNA induces the SOS response and expression of the TisB toxin, an endogenous
antimicrobial peptide that causes persister formation by opening an ion channel.[38 - 40] This
decreases the proton motive force and ATP levels, leading to target shutdown and a dormant,
drug-tolerant state.
	
Antitoxin gene                               Toxin gene
	
Toxin/Antitoxin 
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Figure 3. Co-expression and regulation of the TA loci. The anti-toxin regulates toxin activity by forming a tight com‐
plex with the toxin. The antitoxin is generally produced at a higher rate than the toxin and is degraded by cellular
proteases.
Since both toxin and anti-toxin transcripts are co-expressed from a single promoter, the
imbalance between the two transcripts is primarily caused by accumulation of specific
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proteases, such as the Lon protease in E. coli, that target the anti-toxin for degradation. Deletion
of lon, but not other protease-encoding genes, led to a decrease in persistence, indicating that
Lon plays in specific role in induction of persistence.[33] Lon was also identified in a screen of
a P. aeruginosa PAO1 luciferase fusion library as a differentially-regulated gene upon exposure
to a sub-inhibitory concentration of gentamicin and was shown to be essential for biofilm
formation.[41]
5. Isolation of bulk and single cell persisters
Persisters are a difficult cell population to manipulate, due to their transient nature, low
frequency, and mechanistic heterogeneity. A variety of methods have been utilized for
persister enrichment and have leveraged hipA mutant E. coli strains as the starting material to
maximize persister numbers. Persister cells have been isolated based on sedimentation of
surviving cells following antibiotic treatment.[3, 14] Transcriptomics profiling from the
persister population indicated that genes involved in energy production were downregulated,
consistent with a dormant phenotype. However, since each antibiotic and microbe exhibits
unique killing and survival kinetics, respectively, treatment to isolate persisters is highly
dependent on the individual system. Prolonged exposure to antibiotic agents may also activate
stress response mechansims, which have been recently linked to induction of persistence.
Another isolation method utilized an E. coli strain expressing a green fluorescent protein (GFP)
reporter fused to a ribosomal RNA promoter rrnBP1.[42] Since persisters display low metabolic
activty, sorting of dimly green cells by FACS will concentrate persisters that exhibit little of no
transcription from the rrnBP1 promoter. Finally, persisters have also been isolated by using a
combination of alkaline and enzymatic lysis that targets the cell membrane and kills normally
growing cells.[43] This strategy took 25 min compared to >3 hrs for previous methods and
hence is less likely to induce a stable stress response. Furthermore, persisters isolated with this
protocol did not exhibit activation of the SOS response, indicating that stress response was not
activated.
6. Therapeutic strategies that target bacterial persistence
Initially, investigators sought to identify the genetic determinants that mediate persister
formation as potential targets to prevent or reverse persistence. Given the number of disparate
genes that appear to be involved in persistence, such an approach may prove to be difficult.
Nevertheless, identification of bacterial proteins that are essential even in persisters can
provide novel targets for drug development. Since persisters exist in a slowed metabolic state,
it is likely that changes in environmental parameters can shift pathogen metabolism from
persistence to a replicating state. In the last several years, compounds have been identified that
have exhibited promise in the switching of persisters into growing cells susceptible to antibiotic
killing or in the direct killing of persisters. (Table 2) These strategies can be integrated with
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current antibiotics regimens to develop novel viable therapies for treatment of infectious
disease.
6.1. Metabolite stimulation of aminoglycoside-mediated bacterial killing
A promising strategy for the eradication of persistent bacteria is the combination of an
antibiotic that kills actively replicating bacteria with a metabolite that may enhance the
susceptibility of the persistent bacteria to antibiotics. An elegant example of this strategy was
the addition of metabolites to stimulate cellular metabolism and switch E. coli and S. aureus
persisters back to the wild-type state to be susceptible to aminoglycosides.[44] Multiple carbon
sources that maximize coverage of glycolysis, the pentose-phosphate pathway and the Entner-
Doudoroff pathway were tested for their ability to potentiate aminoglycosides against E. coli
persisters. Metabolites that enter upper glycolysis, including glucose, mannitol, and fructose,
and one that enters lower glycolysis, pyruvate, led to a reduction in persister viability in
response to the aminoglycoside gentamicin, by three orders of magnitude. Other metabolites
that enter the latter two pathways (e.g. arabinose and ribose) did not have a significant effect
on persister death. This potentiation was found to be specific to aminoglycosides, and did not
occur in persisters exposed to quinolone or β-lactam antibiotics, which target DNA and the
cell wall, respectively. The metabolic stimuli were found to generate a proton-motive force
(PMF), which facilitates aminoglycoside uptake and subsequent bacterial killing. Treatment
of persisters with an inhibitor of PMF, the ionophore CCCP, abolished aminoglycoside
potentiation by the metabolite/gentamicin treatment. These results indicate that persisters,
although dormant, are nevertheless primed for metabolic uptake and energy metabolism.
In both an E. coli biofilm model and a chronic biofilm-associated infection in mice, a combi‐
nation of mannitol and gentamicin reduced biofilm viability by several orders of magnitude
compared to antibiotic alone. In the infected mice, the dual treatment inhibited bacterial spread
to the kidneys, compared to no treatment or antibiotic alone, demonstrating the feasibility for
potential clinical use. Metabolite-enabled killing of persisters was also shown to be effective
in the Gram-positive pathogen Staphylococcus aureus, although with fructose as the most
effective metabolite, due to the differential expression of metabolite transporters in S. aureus.
Thus, delivery of PMF-stimulating metabolites may be a novel strategy to complement current
aminoglycoside treatments to generate more effective antibacterial therapies.
6.2. Hyperactivation of ClpP protease kills persisters
Modulation of target protein function that is lethal for microbes is a novel approach for
persister cell elimination. In a recent paper, activation of the ClpP protease by the antibiotic
acyldepsipeptide 4 (ADEP4) was shown to kill persister cells by degrading over 400 cellular
proteins.[45] ADEP exhibits anti-bacterial activity against Gram-positive bacteria in vitro and
in several rodent models of bacterial infection.[46] ClpP is a proteolytic subunit that normally
pairs with different ATPase regulatory subunits to degrade misfolded proteins in the bacterial
cytoplasm. Binding of ADEP to ClpP maintains the catalytic chamber of ClpP in an open
configuration to enable promiscuous cleavage of proteins and decouple protein degradation
from dependence on ATP hydrolysis. Null mutants of clpP were resistant to ADEP4, but were
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found to be highly resistant to killing by multiple antibiotics. This uncontrolled proteolysis
ultimately resulted in bacterial autolysis and cell death. Treatment with ADEP4 exhibited a
decrease in cell count of S. aureus stationary cells by 4 log10 in two days. Conventional antibi‐
otics, including rifampicin, linezolid, and ciprofloxacin, were inactive against stationary phase
S. aureus. However, treatment with a combination of ADEP4 and a conventional antibiotic led
to eradication of S. aureus persisters in growing and stationary cultures. Furthermore, this
combination treatment cleared a chronic biofilm infection in a mouse model that was previ‐
ously untreatable with just conventional antibiotics.[45] These studies demonstrate that
persisters are not invulnerable to killing and that ADEP4 is an effective antibiotic against
persisters in a deep-seated biofilm infection. Conventional antibiotics were likely not effective
against persisters due to pathogen tolerance rather than the inability to diffuse within the
biofilm.
Table 2. Strategies to defeat bacterial persistence
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6.3. Drug screening against metabolically-inactive bacteria
Small molecule library screens have been performed to identify compounds that specifically
target persisters. A quinolone-derived library was screened against non-multiplying S.
aureus using a long-term stationary phase culture.[47] One compound in particular, termed
HT61, exhibited 6 logs killing compared to 1 log for commercially-available antibiotics, such
as amoxicillin and linezolid, in S. aureus persisters and clinical methillicin-resistant S. aureus
strains. HT61 acts via depolarization of the bacterial cell membrane and subsequent break‐
down of the cell wall. HT61 also displayed significant bactericidal effects against other Gram
positive pathogens, including Streptococcus pyogenes and Streptococcus agalactiae, but was less
potent for actively-replicating S. aureus and not effective against Gram negative bacteria such
as E. coli and Klebsiella aerogenes. In a mouse skin bacterial colonization model, HT61 effectively
killed surface S. aureus and did not induce adverse effects in a minipig skin model. Importantly,
HT61-resistant S. aureus were not detected even after 50 passages of exposure, suggesting that
compounds that target persisters may bypass development of antibiotic resistance in normally
replicating bacteria.
Another screen was performed to identify compounds from a library composed of 6800
chemicals, based on scaffolds and physicochemical properties, that can effectively kill persist‐
ers.[48] Compounds were downselected based on enhanced killing of E. coli K-12 in combi‐
nation with both ampicillin and norfloxacin, two antibiotics with different mechanisms of
action. In particular, one compound denoted C10, 3-[4-(4-methoxyphenyl)piperazin-1-
yl]piperidin-4-yl biphenyl-4-carboxylate, exhibited a marked decrease in E. coli and Pseudo‐
monas aeroginosa persistence frequency in combination with fluoroquinolone antibiotics, but
did not affect normal antibiotic-sensitive cells. While persisters were killed when treated with
a combination of C10 and norfloxacin, they also exhibited fast re-growth in the presence of
C10 alone, suggesting that C10 may induce reversion of dormant persisters into replicating
antibiotic-sensitive cells. It will be necessary to identify the binding target of C10 to more fully
understand the mechanism of action on bacterial persistence.
6.4. Combination therapy to treat tuberculosis
Combination treatments that target both replicating and persistent bacteria will likely prove
to be an effective strategy to combat chronic infections. A good example of this approach is
the multiple drug treatment of tuberculosis (TB), a global disease mediated by Mycobacterium
tuberculosis, that causes ~2 million deaths per year. Dormant TB can survive within a host for
decades, thus requiring long-term treatment. Treatment of active M. tuberculosis by a front-line
cocktail of four drugs, isozianid, rifampicin, pyrazinamide, and ethambutol, can be effective
in controlling the disease in the first several months. Isoniazid is effective against rapidly
growing bacilli in lesions, whereas rifampicin and pyrazinamide are thought to be more
effective in killing persistent bacilli.[49] These persistent bacilli localize in macrophages within
tissue cavities. Upon exposure in a low O2 (hypoxic) and nutrient environment, they enter a
low-metabolic, dormant state by downregulation of protein and nucleic acid synthesis and
formation of a thick cell wall. TB persister cells escape both host immune detection and killing
by isoniazid, which can lead to disease relapse upon exit out of the dormant state in the host.
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Interestingly, the mechanism of action of the front-line drug pyrazinamide, known for >50 yrs,
has only recently been deciphered. Pyrazinamide is activated by a mycobacterial amidase to
yield the bioactive compound pyrazinoic acid, which has been linked to multiple essential
cellular processes, including ribosome function[50], fatty acid synthase II[51], and respiratory
activity.[52] Trapping of pyrazinoic acid in the cell leads to a rise in acidity, which kills the
pathogen.[53] Other existing antibiotics, such as moxifloxacin and gatifloxacin, have also been
shown to enhance rates of M. tuberculosis persister death when combined with conventional
drug treatments.[54]
Although in a latent state, M. tuberculosis still performs respiratory energy conversion to
maintain requisite metabolic functions, providing a potential target for novel drug develop‐
ment. Dormant mycobacteria were found to express a functional ATP synthase to generate
energy that drives basal cellular reactions. A newly-discovered inhibitor of ATP synthase,
diarylquinoline TMC207, was recently identified as a potent anti-mycobacterial compound
against replicating M. tuberculosis.[55] Significantly, nanomolar concentrations of TMC207
were able to kill dormant pathogen by blocking ATP synthase activity at a higher efficacy than
observed for replicating mycobacteria, despite ATP synthase being transcriptionally downre‐
gulated in latent M. tuberculosis.[56] TMC207 also exhibited potent sterilization in an infected
lung mouse model, comparable to the triple drug combination of rifampicin, isozianid, and
pyrazinamide. The high efficacy of TMC207 may stem from killing of both actively-growing
and dormant pathogen. These results suggest that basal ATP synthase activity is essential for
the survival of dormant M. tuberculosis, and ATP homeostasis may represent a viable target
for development of persister-directed drugs. TMC207 is presently in Phase II clinical trials for
TB treatment. Furthermore, medicinal chemistry optimization efforts led to generation of novel
diarylquinoline chemotypes that targeted Gram-positive pathogens, including S. aureus in
replicating planktonic and metabolically resting biofilm states, potentially broadening the
antibacterial spectrum of diarylquinoline-based antibiotics.[57]
To further identify novel inhibitors against dormant mycobacteria, a hypoxic model system
was established to screen >600,000 compounds for those that lowered ATP content in a non-
replicating M. bovis BCG recombinant strain.[58] The screen yielded 140 non-cytotoxic
compounds, including imidazopyridines, benzimidazoles, and thiopenes, which modulated
respiratory function against both replicating and non-replicating mycobacteria. Reduction of
cellular ATP levels was shown to correlate with cell death in bacteria treated with the three
compound clusters. Thus, these clusters may form the basis of antibiotic compound develop‐
ment against mycobacteria.
6.5. Bacterial factors that trigger exit from dormancy
Sporulation is another form of persistence in which both pathogen and environmental
microbes enter a metabolically-inactive state and become resistant spores under unfavorable
conditions. For example, in nutrient-poor environments, Bacillus and Clostridium species
undergo tightly regulated transcriptional and morphological changes to form a dormant but
robust spore that is resistant to extreme stress conditions, such as high temperatures, desicca‐
tion, and toxicity. In the laboratory, Bacillus subtilis spores have been shown to germinate and
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exit the spore state in response to treatment with various nutrients, such as amino acids.[59]
Binding of these nutrients to receptors on the inner membrane of the spore leads to rehydration
of the cell interior and breakdown of the peptidoglycan spore layer. B. subtilis has also been
shown to exit dormancy in response to peptidoglycan-derived muropeptides, consisting of a
disaccharide-tripeptide with a meso-diaminopimelic acid (m-DAP) residue in the third
position.[60] Peptidoglycan from growing cells, but not stationary cells, have been shown to
more effectively induce germination, suggesting that these muropeptides may function as
signaling molecules that can stimulate dormant cells. In response to muropeptide binding to
its extracellular domain, the serine/threonine kinase PrkC has been shown to phosphorylate
elongation factor G (EF-G), which modulates ribosomal activity and initiation of translation
to induce microbial exit from dormancy.[60]
Other protein factors expressed by microbes have been reported to stimulate growth of
dormant cells. The environmental microbe, Micrococcus luteus, secretes a resuscitation-
promoting factor (Rpf), which can stimulate exit from dormancy when added to M. luteus
cultures.[61] M. luteus Rpf has been shown to hydrolyze peptidoglycan at picomolar concen‐
trations and stimulate aged cultures of M. tuberculosis, thus exhibiting cross-species activity.
[62, 63] M. tuberculosis expresses five endogenous Rpfs that function in reactivation of chronic
tuberculosis in animal models.[64] Although the exact function of Rpfs remains unclear, it has
been suggested that Rpf-mediated proteolysis of peptidoglycan can generate muropeptides
for PrkC-like kinases to activate protein translation.[65]
7. Conclusion
The rise in antimicrobial drug resistance, alongside the failure of conventional research efforts
to discover new antibiotics, will eventually lead to a public health crisis that can drastically
curtail our ability to combat infectious disease. Bacterial persistence is an underexplored
mechanism by which to develop novel treatments to complement or extend the current
repertoire of antibiotics.[66 - 68] Although persisters do not cause overt disease, they act as a
pool from which bacteria can emerge from dormancy to cause recurrent infection. Mechanisms
of persister formation appear to be highly redundant across different bacterial species, which
contributes to the difficulty in identification of universal mechanisms to target and eradicate
persistence. To date, the more successful strategies in the lab have been to target cell functions,
such as basal energy metabolism and cell wall integrity, that are also essential for persister cell
maintenance.[69] Of particular note, addition of metabolites such as mannitol or fructose was
shown to potentiate aminoglycoside-mediated killing by generating a proton motive force to
stimulate aminoglycoside uptake.[44] Several medicinal chemistry strategies to screen for
small molecules effective against persisters have also identified lead targets for potential
optimization and rational drug design.
By developing treatments against both persisters and replicating pathogens, it may be possible
to shorten antibiotic regimens, especially for deep-seated diseases such as tuberculosis, and
reduce relapse rates in patients. Another advantage to combination therapies is potential
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extension of the useful life of current antibiotics to kill pathogen at a faster rate, and thus slow
down the further emergence of antibiotic resistance. Additional strategies to optimize pulse-
dosing regimens using multiple antibiotics that include anti-persister drugs may be able to
sterilize particularly recalcitrant chronic infections. These types of therapies may be designed
for the individual patient as part of an increasingly personalized approach to medicine. Aside
from the clinical relevance of bacterial persisters, non-genetic heterogeneity has been found to
play important roles in other systems, including susceptibility of cancer cells to treatment[70],
host response to viral infection[71], and bacterial responses to other stresses.[72] Thus,
understanding the mechanisms of cell-to-cell variability will provide insights into the general
adaptation of life to variable environments.
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